
Alnylam Drug Approval Brings Cardiomyopathy Competition to Pfizer, BridgeBio Pharma
Alnylam Pharmaceuticals has landed a long-awaited FDA decision that expands use of its drug, Amvuttra, to the treatment of a type of cardiomyopathy that’s growing in prevalence. It’s the second FDA approval in this indication in four months and the third …